1. Home
  2. OPFI vs XBIT Comparison

OPFI vs XBIT Comparison

Compare OPFI & XBIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo OppFi Inc.

OPFI

OppFi Inc.

HOLD

Current Price

$6.25

Market Cap

556.4M

Sector

Finance

ML Signal

HOLD

Logo XBiotech Inc.

XBIT

XBiotech Inc.

N/A

Current Price

$2.17

Market Cap

66.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
OPFI
XBIT
Founded
2009
2005
Country
United States
United States
Employees
N/A
N/A
Industry
Finance: Consumer Services
Pharmaceuticals and Biotechnology
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
556.4M
66.8M
IPO Year
2020
2015

Fundamental Metrics

Financial Performance
Metric
OPFI
XBIT
Price
$6.25
$2.17
Analyst Decision
Buy
Analyst Count
2
0
Target Price
★ $14.25
N/A
AVG Volume (30 Days)
★ 808.7K
43.6K
Earning Date
05-07-2026
05-08-2026
Dividend Yield
★ 2.72%
N/A
EPS Growth
★ 175.00
N/A
EPS
★ 0.74
N/A
Revenue
N/A
N/A
Revenue This Year
$97.52
N/A
Revenue Next Year
$10.95
N/A
P/E Ratio
$8.43
★ N/A
Revenue Growth
★ N/A
N/A
52 Week Low
$6.20
$2.09
52 Week High
$12.28
$3.44

Technical Indicators

Market Signals
Indicator
OPFI
XBIT
Relative Strength Index (RSI) 31.22 40.04
Support Level N/A N/A
Resistance Level $7.35 $2.48
Average True Range (ATR) 0.28 0.04
MACD -0.07 0.00
Stochastic Oscillator 4.55 15.38

Price Performance

Historical Comparison
OPFI
XBIT

About OPFI OppFi Inc.

OppFi Inc. is a tech-enabled, mission-driven specialty finance platform that broadens the reach of community banks to expand credit access for everyday Americans. It recognizes revenue from finance charges on installment and SalaryTap contracts using the interest method.

About XBIT XBiotech Inc.

XBiotech Inc is a biopharmaceutical company that discovers and develops True Human monoclonal antibodies derived from human donors to replicate the human immune response in the treatment of various diseases. It has developed a pipeline of product candidates using True Human antibodies targeting both inflammatory and infectious diseases. The company's developement pipeline comprises: Natrunix, an antibody targeting IL-1a in oncology (pancreatic cancer), a clinical stage therapeutic for Methicillin Resistant Staphylococcus aureus (MRSA), and several pre-clinical stage therapeutics, including: an oral delivery antibody therapeutic for colon infection by C. difficile; an injectable therapy for varicella zoster (adult chicken pox), the causative agent for shingles; and an influenza therapy.

Share on Social Networks: